A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
The Purpose of the Study is to Compare the Efficacy and Safety of BMS-986489 (Anti-fucosyl-GM1+ Nivolumab Fixed Dose Combination) in Combination with Carboplatin plus Etoposide to that of Atezolizumab with Carboplatin plus Etoposide as First-Line Therapy in Participants with Extensive-Stage Small Cell Lung Cancer.
Checked against the public recordLast updated Aug 14, 2026 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Phase 3
- Sponsor
- Bristol-Myers Squibb
- Interventions being studied
- Biological: BMS-986489 (BMS-986012+Nivolumab); Biological: Atezolizumab; Drug: Carboplatin; Drug: Etoposide
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria * Participants must have diagnosis of Extensive-Stage Small Cell Lung Cancer (ES-SCLC). * Participants must be Healthy enough to do their normal activities with little or no help based on the ECOG performance scale. * Participants must have at least one tumor that can be measured using special imaging techniques like a CT scan or MRI at a site other than the brain and nervous system Exclusion Criteria * Participants have already received certain types of treatment for extensive stage small cell lung cancer * Participants have certain health conditions, like spread of small cell lung cancer to the brain that are causing symptoms, certain lung diseases, heart diseases, infections, autoimmune diseases, other cancers, or a type of nerve damage called peripheral sensory neuropathy * Other protocol-defined Inclusion/Exclusion criteria apply.
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Southern Cancer Center, PCDaphne, Alabama
- Local Institution - 0283Hot Springs, Arkansas
- Florida Cancer Specialists - SouthFort Myers, Florida
- Mid Florida Hematology and Oncology CenterOrange City, Florida
- Florida Cancer Specialists - NorthSt. Petersburg, Florida
- Northwest Georgia Oncology Centers, a Service of Wellstar Cobb HospitalMarietta, Georgia
- Illinois Cancer CarePeoria, Illinois
- Local Institution - 0037Minneapolis, Minnesota
- University of New Mexico Comprehensive Cancer CenterAlbuquerque, New Mexico
- Duke Cancer InstituteDurham, North Carolina
- Sanford Medical CenterBismarck, North Dakota
- Sanford Fargo Medical CenterFargo, North Dakota
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Aug 14, 2026. Always confirm current availability with the study team.